* BioCryst Pharmaceuticals Inc., of Birmingham, Ala., directlyplaced 1 million shares at $8 each, raising $8 million. On Dec. 31,1995, the company reported $11.4 million in cash. It now has 10.5million shares outstanding.

* VIMRx Pharmaceuticals Inc., of Stamford, Conn., said a group ofinvestors led by Ronald Perelman, chairman of MacAndrews &Forbes Holdings Inc., agreed to buy $4.2 million in VIMRx equityconsisting of 2.8 million shares and 1.4 million warrants, eachexercisable for one share. In connection with the deal, DonaldDrapkin, a vice chairman at MacAndrews & Forbes, was electedVIMRx chairman.

* Biogen Inc., of Cambridge, Mass., said results of a Phase II/III trialof Hirulog showed the thrombin inhibitor achieved a statisticallysignificant improvement over heparin in opening blood vessels inheart attack patients. The trial was ongoing when Biogen said inNovember 1994 it was discontinuing its Hirulog program after aPhase III study failed to demonstrate statistical significance,compared with heparin, in preventing cardiac complicationsassociated with angioplasty. Biogen is seeking a partner to continuedevelopment.

* NeXstar Pharmaceuticals Inc., of Boulder, Colo., got approval tomarket DaunoXome as a primary therapy for AIDS-related Kaposi'ssarcoma in Germany, the Netherlands, Finland and Norway.

* Emisphere Technologies Inc., of Hawthorne, N.Y., filed aninvestigational new drug application to conduct a Phase I studyevaluating its proprietary technology for the oral delivery of heparin.If successful, the company would run a Phase II study evaluating theformulation over two weeks as a prophylaxis for deep veinthrombosis following knee and hip surgeries.

* Athena Neurosciences Inc., of South San Francisco, said itsEuropean subsidiary was asked by the Committee on Safety andMedicine to respond to certain questions regarding its product licenseapplication before the CSM` would provide final advice regarding itsrecommendation to the U.K.'s Medicines Control Agency.

* Gensia Inc., of San Diego, received product licenses to market theGenESA system in Belgium and Portugal. Gensia now has approvalto market the system, designed for use in diagnosing coronary arterydisease, in nine European countries.

* Atrix Laboratories Inc., of Fort Collins, Colo., received FDAclearance to market the Atrisorb Barrier for Guided TissueRegeneration, a dental product. It is the first product the companywill market based on its Atrigel biodegradable polymer technology.

* Agennix Inc., of Houston, and Royal Gist-Brocades N.V., of Delft,the Netherlands, are collaborating on development, manufacturingand commercialization of human lactoferren. Gist-Brocades, which istaking a 10 percent position in Agennix, has patents and applicationson the production of proteins in Aspergillus species. Agennix haspatents covering human lactoferrin DNA sequences and proteins.

(c) 1997 American Health Consultants. All rights reserved.